反对观点：所有免疫耐受型乙型肝炎病毒患者都无需接受治疗。
CON: All Patients With Immune-Tolerated Hepatitis B Virus Do Not Need to Be Treated.
作者信息
Attar Bashar M
机构信息
Division of Gastroenterology and Hepatology Cook County Health Chicago IL.
出版信息
Clin Liver Dis (Hoboken). 2020 Feb 25;15(1):25-30. doi: 10.1002/cld.893. eCollection 2020 Jan.
Abstract
http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/15-1-reading-attar a video presentation of this article.
相似文献
1
CON: All Patients With Immune-Tolerated Hepatitis B Virus Do Not Need to Be Treated.反对观点：所有免疫耐受型乙型肝炎病毒患者都无需接受治疗。
Clin Liver Dis (Hoboken). 2020 Feb 25;15(1):25-30. doi: 10.1002/cld.893. eCollection 2020 Jan.
2
Immunopathogenesis of Autoimmune Hepatitis.自身免疫性肝炎的免疫发病机制
Clin Liver Dis (Hoboken). 2020 Apr 4;15(3):129-132. doi: 10.1002/cld.873. eCollection 2020 Mar.
3
A Practical Approach to Polycystic Liver Disease.多囊肝病的实用治疗方法
Clin Liver Dis (Hoboken). 2019 Dec 20;14(5):176-179. doi: 10.1002/cld.864. eCollection 2019 Nov.
4
Bile Acid Biology, Pathophysiology, and Therapeutics.胆汁酸生物学、病理生理学与治疗学
Clin Liver Dis (Hoboken). 2020 Apr 4;15(3):91-94. doi: 10.1002/cld.861. eCollection 2020 Mar.
5
Parenteral Nutrition-Associated Liver Disease.肠外营养相关肝病
Clin Liver Dis (Hoboken). 2020 Mar 26;15(2):59-62. doi: 10.1002/cld.888. eCollection 2020 Feb.
6
Nutritional Management of Cholestasis.胆汁淤积的营养管理
Clin Liver Dis (Hoboken). 2020 Feb 25;15(1):9-12. doi: 10.1002/cld.865. eCollection 2020 Jan.
7
Optimizing Vaccination in Adult Patients With Liver Disease and Liver Transplantation.优化肝病成年患者及肝移植受者的疫苗接种
Clin Liver Dis (Hoboken). 2020 Mar 26;15(2):63-68. doi: 10.1002/cld.898. eCollection 2020 Feb.
8
Isolated Elevated Bilirubin.孤立性胆红素升高
Clin Liver Dis (Hoboken). 2020 May 7;15(4):153-156. doi: 10.1002/cld.944. eCollection 2020 Apr.
9
Novel Therapies for Managing Cholestasis.治疗胆汁淤积的新型疗法
Clin Liver Dis (Hoboken). 2020 Apr 4;15(3):95-99. doi: 10.1002/cld.886. eCollection 2020 Mar.
10
Managing the Symptoms and Complications of Cholestasis.胆汁淤积症状及并发症的管理
Clin Liver Dis (Hoboken). 2020 Apr 4;15(3):120-124. doi: 10.1002/cld.901. eCollection 2020 Mar.
引用本文的文献
1
The Epidemiology, Transmission, Genotypes, Replication, Serologic and Nucleic Acid Testing, Immunotolerance, and Reactivation of Hepatitis B Virus.乙型肝炎病毒的流行病学、传播、基因型、复制、血清学与核酸检测、免疫耐受及再激活
Gastro Hep Adv. 2023 Oct 24;3(2):139-150. doi: 10.1016/j.gastha.2023.10.008. eCollection 2024.
2
Latest insights into the epidemiology, characteristics, and therapeutic strategies of chronic hepatitis B patients in indeterminate phase.慢性乙型肝炎不确定期患者的流行病学、特征和治疗策略的最新见解。
Eur J Med Res. 2024 Jun 21;29(1):343. doi: 10.1186/s40001-024-01942-0.
3
Nomogram for evaluating obvious liver inflammation in treatment-naïve HBeAg positive chronic hepatitis B virus infection patients with normal ALT.用于评估 ALT 正常的初治 HBeAg 阳性慢性乙型肝炎病毒感染患者明显肝脏炎症的列线图。
Virulence. 2023 Dec;14(1):2158710. doi: 10.1080/21505594.2022.2158710.
4
Viral hepatitis: Milestones, unresolved issues, and future goals.病毒性肝炎：里程碑、未解决的问题和未来目标。
World J Gastroenterol. 2021 Jul 28;27(28):4603-4638. doi: 10.3748/wjg.v27.i28.4603.
本文引用的文献
1
Understanding the Natural History of Hepatitis B Virus Infection and the New Definitions of Cure and the Endpoints of Clinical Trials.了解乙型肝炎病毒感染的自然史以及治愈的新定义和临床试验的终点。
Clin Liver Dis. 2019 Aug;23(3):401-416. doi: 10.1016/j.cld.2019.04.002. Epub 2019 Jun 1.
2
Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy?免疫耐受型乙肝病毒与肝癌：是时候重新审视我们的治疗耐受水平了？
AME Med J. 2018 Feb;3. doi: 10.21037/amj.2018.02.01. Epub 2018 Feb 10.
3
Immunotolerant Chronic Hepatitis B Infection: When Do I Treat?免疫耐受期慢性乙型肝炎感染：何时进行治疗？
J Clin Exp Hepatol. 2019 Mar-Apr;9(2):277-279. doi: 10.1016/j.jceh.2018.06.001. Epub 2018 Jun 26.
4
Hepatitis B Treatment: What We Know Now and What Remains to Be Researched.乙肝治疗：我们目前所了解的情况以及有待研究的内容。
Hepatol Commun. 2018 Nov 15;3(1):8-19. doi: 10.1002/hep4.1281. eCollection 2019 Jan.
5
Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection.恩替卡韦和聚乙二醇干扰素 Alfa-2a 治疗乙型肝炎 e 抗原阳性免疫耐受期慢性乙型肝炎病毒感染。
Hepatology. 2019 Jun;69(6):2338-2348. doi: 10.1002/hep.30417. Epub 2019 Mar 14.
6
Combination of Entecavir/Peginterferon Alfa-2a in Children With Hepatitis B e Antigen-Positive Immune Tolerant Chronic Hepatitis B Virus Infection.恩替卡韦/聚乙二醇干扰素α-2a 联合治疗乙型肝炎 e 抗原阳性免疫耐受期慢性乙型肝炎病毒感染患儿。
Hepatology. 2019 Jun;69(6):2326-2337. doi: 10.1002/hep.30312. Epub 2019 Feb 20.
7
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.慢性乙型肝炎的预防、诊断和治疗最新进展：美国肝病研究学会2018年乙型肝炎指南
Hepatology. 2018 Apr;67(4):1560-1599. doi: 10.1002/hep.29800.
8
High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.免疫耐受期慢性乙型肝炎患者发生肝细胞癌和死亡的风险较高。
Gut. 2018 May;67(5):945-952. doi: 10.1136/gutjnl-2017-314904. Epub 2017 Oct 21.
9
Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients.免疫耐受期慢性乙型肝炎患者停用替诺福韦后的四年结局
J Clin Gastroenterol. 2018 Apr;52(4):347-352. doi: 10.1097/MCG.0000000000000852.
10
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.EASL 2017 临床实践指南：乙型肝炎病毒感染管理。
J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18.
Zotero 插件